Stem definition | Drug id | CAS RN |
---|---|---|
prostaglandins | 913 | 363-24-6 |
Dose | Unit | Route |
---|---|---|
0.50 | mg | O |
0.50 | mg | V |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.05 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 23, 1977 | FDA | PHARMACIA AND UPJOHN | |
Jan. 23, 2020 | PMDA | Ferring Pharmaceuticals Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Uterine hyperstimulation | 282.70 | 64.11 | 30 | 750 | 29 | 50604315 |
Exposure during pregnancy | 166.69 | 64.11 | 64 | 716 | 120951 | 50483393 |
Uterine tachysystole | 151.39 | 64.11 | 16 | 764 | 14 | 50604330 |
Uterine hypertonus | 133.94 | 64.11 | 18 | 762 | 237 | 50604107 |
Caesarean section | 115.54 | 64.11 | 30 | 750 | 15609 | 50588735 |
Uterine rupture | 115.10 | 64.11 | 19 | 761 | 1056 | 50603288 |
Meconium in amniotic fluid | 92.72 | 64.11 | 13 | 767 | 237 | 50604107 |
Anaphylactoid syndrome of pregnancy | 85.18 | 64.11 | 10 | 770 | 38 | 50604306 |
Premature separation of placenta | 80.62 | 64.11 | 15 | 765 | 1663 | 50602681 |
Disseminated intravascular coagulation | 80.34 | 64.11 | 23 | 757 | 17112 | 50587232 |
Postpartum haemorrhage | 79.95 | 64.11 | 15 | 765 | 1739 | 50602605 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 197.87 | 61.87 | 56 | 477 | 77619 | 64420580 |
Uterine hyperstimulation | 125.36 | 61.87 | 13 | 520 | 25 | 64498174 |
Uterine hypertonus | 119.63 | 61.87 | 15 | 518 | 218 | 64497981 |
Caesarean section | 115.49 | 61.87 | 25 | 508 | 11249 | 64486950 |
Meconium in amniotic fluid | 114.45 | 61.87 | 13 | 520 | 75 | 64498124 |
Premature separation of placenta | 95.76 | 61.87 | 15 | 518 | 1129 | 64497070 |
Uterine tachysystole | 89.68 | 61.87 | 9 | 524 | 10 | 64498189 |
Maternal exposure during pregnancy | 80.63 | 61.87 | 30 | 503 | 95854 | 64402345 |
Uterine rupture | 71.97 | 61.87 | 11 | 522 | 702 | 64497497 |
None
Source | Code | Description |
---|---|---|
ATC | G02AD02 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
FDA CS | M0017805 | Prostaglandins |
FDA EPC | N0000175454 | Prostaglandin Analog |
CHEBI has role | CHEBI:36063 | oxytocic agents |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
MeSH PA | D010120 | Oxytocics |
MeSH PA | D012102 | Reproductive Control Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Incomplete miscarriage | indication | 156072005 | |
Induction of labor | indication | 236958009 | |
Cervical ripening procedure | indication | 236959001 | |
Pregnancy with abortive outcome | indication | 363681007 | |
Hydatidiform mole, benign | indication | 417044008 | |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Multiple pregnancy | contraindication | 16356006 | |
Grand multipara | contraindication | 18656007 | |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Disproportion between fetus and pelvis | contraindication | 25749005 | |
Genital herpes simplex | contraindication | 33839006 | DOID:8704 |
Placenta previa | contraindication | 36813001 | DOID:11060 |
Inflammation of cervix | contraindication | 37610005 | DOID:2568 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Low blood pressure | contraindication | 45007003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Disseminated intravascular coagulation | contraindication | 67406007 | DOID:11247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Stenosis of cervix | contraindication | 83536006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Female genital tract infection | contraindication | 125585007 | |
Seizure disorder | contraindication | 128613002 | |
Fetal distress | contraindication | 130955003 | |
Spontaneous rupture of membranes | contraindication | 169734005 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Deliveries by cesarean | contraindication | 200144004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Abnormal uterine bleeding unrelated to menstrual cycle | contraindication | 312984006 | |
Endocervical Lesions | contraindication | ||
Uterine Hypertonic Patterns | contraindication | ||
Gynecological Surgery | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.79 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | Ki | 9.48 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 8.77 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 9.77 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 8.04 | CHEMBL | CHEMBL | |||
Prostaglandin D2 receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
Cation channel sperm-associated protein 1 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 2 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 3 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 4 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 6.90 | IUPHAR | ||||
Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 5.30 | IUPHAR | ||||
Prostacyclin receptor | GPCR | IC50 | 6.59 | CHEMBL | |||||
Thromboxane A2 receptor | GPCR | AGONIST | Ki | 4.50 | IUPHAR | ||||
Prostaglandin E2 receptor EP1 subtype | GPCR | Ki | 8.22 | CHEMBL | |||||
Prostaglandin E2 receptor EP2 subtype | GPCR | Ki | 7.66 | CHEMBL | |||||
Prostaglandin E2 receptor EP3 subtype | GPCR | Ki | 8.30 | CHEMBL | |||||
Prostaglandin E2 receptor EP4 subtype | GPCR | Ki | 8.51 | CHEMBL | |||||
Solute carrier family 22 member 6 | Transporter | Ki | 5.47 | CHEMBL | |||||
Solute carrier family 22 member 20 | Transporter | Ki | 4.74 | CHEMBL | |||||
Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
Prostaglandin E2 receptor EP2 subtype | GPCR | IC50 | 8.28 | CHEMBL | |||||
Prostaglandin E2 receptor EP4 subtype | GPCR | IC50 | 8.68 | CHEMBL | |||||
Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 5.50 | IUPHAR | ||||
Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | EC50 | 9.39 | IUPHAR | ||||
Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 7.70 | IUPHAR |
ID | Source |
---|---|
4018093 | VUID |
N0000146431 | NUI |
D00079 | KEGG_DRUG |
3478 | RXNORM |
4018093 | VANDF |
C0012472 | UMLSCUI |
CHEBI:15551 | CHEBI |
P2E | PDB_CHEM_ID |
CHEMBL548 | ChEMBL_ID |
DB00917 | DRUGBANK_ID |
D015232 | MESH_DESCRIPTOR_UI |
5280360 | PUBCHEM_CID |
3075 | INN_ID |
K7Q1JQR04M | UNII |
4609 | MMSL |
001309 | NDDF |
387245009 | SNOMEDCT_US |
44798001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Prepidil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3359 | GEL | 0.50 mg | VAGINAL | NDA | 20 sections |
CERVIDIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-2800 | INSERT | 10 mg | VAGINAL | NDA | 26 sections |